


Amendments to the Specification:

Please amend the abstract to read as follows:

ABSTRACT

The use of purine derivatives of formula (I):



in which:


Rx is $-(Z)_n-R_1$ wherein

Z is a divalent radical selected from $-CH_2-$, $-SO_2-$, $-CO-$, $-COO-$, $-CONH-$ and $-(CH_2)_2-NR_6-$,

n is an integer selected from 0 and 1,

R_1 is selected from hydrogen, aryl, $-CH_2$ -aryl, $-SO_2$ -aryl, heterocyclic, $-CH_2$ -heterocyclic, alkyl and $-SO_2$ -alkyl,

Ry is a phenyl radical (optionally substituted) or the radical:



wherein D_1 and D_2 , which are identical or different, are selected from hydrogen, hydroxyl, the linear or branched alkyl or alkoxy radicals containing at most 6 carbon atoms and NHR_5 , or, alternatively, taken together, D_1 and D_2 form a radical selected from $=O$ and $=N-OR_4$,

R_4 is hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl or aryl,

R_5 is hydrogen, alkyl, cycloalkyl, or $-COOtBu$ (Boc), and

R_6 is hydrogen, alkyl or cycloalkyl, wherein the alkyl moiety contains 1 to 6,

optionally substituted, carbon atoms;

as cdk kinase inhibitors for the prevention and treatment of fungal infections. Also disclosed are novel methods and intermediates for the production of compounds of formula I, as well as pharmaceutical compositions containing said compounds.